Treatment of hyperhomocysteinemia and endothelial dysfunction in renal-transplant recipients with vitamin B.
- Author:
Tao XU
1
;
Xiao-feng WANG
;
Xing-ke QU
;
Hai-yun YE
;
Xiao-bo HUANG
;
Xiao-peng ZHANG
;
Shu-kun HOU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Drug Therapy, Combination; Endothelium, Vascular; drug effects; physiopathology; Female; Folic Acid; administration & dosage; Humans; Hyperhomocysteinemia; drug therapy; physiopathology; Kidney Transplantation; Male; Middle Aged; Treatment Outcome; Vitamin B 12; administration & dosage; Vitamin B 6; administration & dosage
- From: Chinese Journal of Surgery 2005;43(14):940-943
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of vitamin B on treatment of hyperhomocysteinemia and endothelial dysfunction in renal-transplant recipients.
METHODSThirty-six stable hyperhomocysteinemic renal-transplant recipients were randomly assigned to vitamin treatment (group A, n = 18, folic acid 5 mg/d, vitamin B(6) 50 mg/d, B(12) 1000 microg/d) or controlled group (group B, n = 18) for 6 months. All subjects underwent assessment of levels for creatinine, creatinine clearance, average pressure, total cholesterol, triglyceride and fasting homocysteine. Endothelial function was evaluated using high-resolution vascular ultrasound.
RESULTSThe levels of homocysteine markedly decreased in group A [(13 +/- 4) micromol/L vs (20 +/- 5) micromol/L, t = 5.3, P < 0.01] after treatment, whereas no significant changes were observed in group B. In group A, endothelium dependent [(12 +/- 5)% vs (9 +/- 5)%, t = 2.9, P < 0.01] and independent [(18 +/- 4)% vs (12 +/- 5)%, t = 3.4, P < 0.01] vasodilatation responses significantly increased after treatment, no significant changes were observed in group B. Endothelium dependent [(9 +/- 6)%, t = 2.8, P < 0.01] and independent [(12 +/- 5)%, t = 3.5, P < 0.01] vasodilatation responses of group A were significantly lower than that of group B after treatment.
CONCLUSIONSVitamin B supplementation can reduce the levels of homocysteine and improve the endothelial function in hyperhomocysteinemic renal-transplant recipients.
